# Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

> **NCT04999839** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 259 (actual)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** NDI-034858 study drug
- **DRUG:** NDI-034858 study drug
- **DRUG:** NDI-034858 study drug
- **DRUG:** NDI-034858 study drug
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04999839
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-09-12
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04999839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04999839, "Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT04999839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*